Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2020-01-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司2019年持续督导培训工作报告（2019年12月）
Regulatory Filings Classification · 90% confidence The document is titled as a "2019 年持续督导培训工作报告" which translates to a "2019 Continuous Supervision Training Work Report." It details a training session conducted by a sponsoring securities company for the listed company, focusing on regulatory updates related to refinancing, mergers and acquisitions, and equity incentives. The content is about a training event and its effectiveness rather than financial results, audit opinions, or management changes. The document length is short (1248 characters), and it is a report on a specific training activity rather than a general regulatory announcement or a report publication announcement. It does not fit into categories like Annual Report, Interim Report, Audit Report, or Earnings Release. It is also not a regulatory filing or announcement of voting results. The closest fitting category is Regulatory Filings (RNS) as it is a regulatory-related report but does not fit other specific categories.
2020-01-03 Chinese
广发证券股份有限公司关于公司2019年持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导定期现场检查报告" which translates to "Continuous Supervision Regular On-site Inspection Report" for the year 2019. It is issued by a sponsoring institution (广发证券股份有限公司) regarding a company (烟台正海生物科技股份有限公司). The content includes detailed checks on corporate governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, and other important matters. It is a regulatory compliance and supervision report rather than a financial report or announcement. The document length is 3653 characters, which is relatively short and focused on inspection findings rather than full financial data or management discussion. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a standalone audit or inspection report related to regulatory oversight. Therefore, the best fitting category is Audit Report / Information (AR). FY 2019
2020-01-03 Chinese
关于使用闲置募集资金及自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is titled '现金管理进展公告' which translates to 'Cash Management Progress Announcement'. It details the company's use of idle raised funds and own funds for cash management, including specific financial products purchased, approval procedures, risk control measures, and the impact on the company. The document includes tables of financial product investments, expected yields, and dates, but it is not a full financial report or earnings release. It is an announcement about the progress and status of cash management activities, not a comprehensive financial statement or audit report. The document length is about 6,496 characters, which is sufficient for a detailed announcement but does not contain full financial statements or management discussion. It is not a certification or officer attestation. The content fits best with a Capital/Financing Update (CAP) as it relates to the company's financing activities and cash management progress. Therefore, the appropriate classification is CAP with high confidence.
2019-12-06 Chinese
关于特定股东减持计划时间过半的进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled '减持进展公告' which translates to 'Announcement of Progress on Shareholder Reduction of Holdings'. It details the progress of a specific shareholder's plan to reduce their shares, including dates, quantities, and compliance with regulatory requirements. The document references regulatory rules about shareholder reductions and confirms that the reduction plan is ongoing but not yet complete. There is no financial statement or comprehensive financial data presented, nor is this a full report or earnings release. The document is an official announcement about the progress of a shareholding reduction plan by a specific shareholder. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company or its shareholders buying back or selling shares. The document length is 2312 characters, which is relatively short but contains detailed progress information, not just a notice of report publication or certification. Therefore, the best classification is POS with high confidence.
2019-11-29 Chinese
关于公司部分医疗器械产品完成延续注册的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1085 characters) about the completion of renewal registration for medical device products by the company. It includes product registration certificate numbers, validity periods, and impact statements. There are no financial statements, detailed financial data, or comprehensive reports. The document serves as an official notice of regulatory approval and its potential impact on the company, fitting the profile of a Regulatory Filing (RNS) rather than a full report or detailed financial disclosure. It is not an Annual Report, Interim Report, or any other detailed financial or governance document. Therefore, the best classification is Regulatory Filings (RNS).
2019-11-20 Chinese
关于持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, timing, and method of share reduction, as well as compliance with relevant regulatory requirements. The document references specific regulations governing shareholder share reduction disclosures and includes risk warnings related to the planned share reduction. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about a major shareholder's planned transaction in their shares, specifically a pre-disclosure of share reduction. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels and related disclosures.
2019-10-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.